Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Hisamitsu Pharmaceutical Co ( (JP:4530) ) has issued an announcement.
Hisamitsu Pharmaceutical has secured shareholder approval for a drastic share consolidation and partial amendment of its Articles of Incorporation at an extraordinary general meeting. The move will reduce its issued common shares from more than 70 million to just three, effectively reshaping its capital structure and shareholder base.
As a result of the consolidation, Hisamitsu’s stock will meet delisting criteria on the Tokyo, Nagoya, and Fukuoka exchanges, and is scheduled to be designated as securities under supervision until May 10, 2026, then delisted on May 11, 2026. After delisting, the shares will no longer trade on those markets, significantly changing liquidity and market access for existing shareholders and concentrating ownership among a limited group of investors.
The most recent analyst rating on (JP:4530) stock is a Hold with a Yen4300.00 price target. To see the full list of analyst forecasts on Hisamitsu Pharmaceutical Co stock, see the JP:4530 Stock Forecast page.
More about Hisamitsu Pharmaceutical Co
Hisamitsu Pharmaceutical Co., Inc. is a Japan-based drugmaker listed on the Tokyo, Nagoya, and Fukuoka exchanges, known for developing and marketing pharmaceutical products. The company operates primarily in the healthcare sector, with a focus on treatments that serve both domestic and international markets, and has been a longstanding presence in Japan’s listed corporate landscape.
Average Trading Volume: 477,460
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen441.1B
For an in-depth examination of 4530 stock, go to TipRanks’ Overview page.